Monthly Archives: July 2016

OSHA Investigates Connecticut Contractor’s Death, As Personal Injury Lawyer Continues To Urge Regulators To Revise Safety Regulations

July 28, 2016 – – LipsigLawyers.com reports on a statement released by the Occupational Safety & Health Administration (OSHA) regarding the unexpected death of a construction contractor in Wilton, CT. As reported by TheHour.com, OSHA has stated that its investigation into the contractor’s death on June 9th, who suffered injuries related to electrocution, could take a significant amount of time to complete. The agency in its public statement announced that it was still compiling the facts of the case, and due to the time involved in some components of the autopsy report, the cause of death could not be released for up to 6 to 8 weeks.

As per OSHA, death by electrocution is the 2nd leading cause of construction worker fatalities in America. The agency stated that in 2014, over 8 percent of construction worker fatalities can be attributed to electrocution, which equates to 74 fatalities.

OSHA is a federal regulatory agency with a mission to ensure the health and safety of over 130 million workers all across the United States working at 8 million various job sites. Given the breadth of workers and sites to oversee, its task is monumental given that there are only 10 regional offices and 90 locally-based offices encompassing 2,200 safety inspectors. The agency is understaffed since each inspector is responsible for over 59,000 workers.

Attorney Thomas Moverman of Lipsig, Shapey, Manus, & Moverman commented on his concern that OSHA is understaffed and stated that there is a need for more manpower to achieve the agency’s mission. Given the number of fatalities and the workers to oversee, he feels the current rules and regulations governing the construction industry needs to be updated and strengthened so that accidents such as this do not continue to frequently occur.

For more information on construction injuries, or for a consultation, contact an attorney with Lipsig, Shapey, Manus & Moverman at (646)-846-4496.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60011636

Ovarian Cancer Pipeline Market 2016 Global Review Covering 271 Companies

RnRMarketResearch.com adds “Ovarian Cancer – Pipeline Review, H1 2016” to its database.

Pune, India – July 28, 2016 /MarketersMedia/ —

Ovarian Cancer Pipeline Market Companies Involved in Therapeutics Development are 3-V Biosciences, Inc. ,4SC AG ,AB Science SA ,AbbVie Inc. ,AbGenomics International, Inc. ,Acetylon Pharmaceuticals, Inc. ,Adaptimmune Therapeutics Plc ,Adgero Biopharmaceuticals, Inc. ,Aduro BioTech, Inc. ,Advanced Accelerator Applications S.A. ,Advantagene, Inc. ,Advaxis, Inc. ,Advenchen Laboratories, LLC ,Aeterna Zentaris Inc. ,Alchemia Limited ,Alethia Biotherapeutics Inc. ,Almac Discovery Limited ,Alpha Cancer Technologies Inc. ,Alteogen Inc. ,Ambrx, Inc. ,Amgen Inc. ,Anavex Life Sciences Corp. ,ANP Technologies, Inc. ,Antoxis Limited ,Apac Biotech Pvt Ltd ,Aphios Corporation ,Aposense Ltd. ,Aprea AB ,arGEN-X BV ,Armour Therapeutics Inc. ,Arno Therapeutics, Inc. ,Arog Pharmaceuticals, Inc. ,ArQule, Inc. ,Arrien Pharmaceuticals, LLC ,Arvinas, Inc. ,Ascentage Pharma Group Corporation, Ltd. ,Astellas Pharma Inc. ,Astex Pharmaceuticals, Inc. ,AstraZeneca Plc ,Atara Biotherapeutics, Inc. ,ATLAB Pharma SAS ,AVEO Pharmaceuticals, Inc. ,Avipep Pty Ltd ,Azaya Therapeutics, Inc. ,Basilea Pharmaceutica AG ,Bavarian Nordic A/S ,Bayer AG ,BeiGene, Ltd. ,BioCancell Ltd ,BioMoti Limited ,BioNTech AG ,BioNumerik Pharmaceuticals, Inc. ,Bioo Therapeutics ,Biscayne Pharmaceuticals, Inc. ,Boehringer Ingelheim GmbH ,Boston Biomedical, Inc. ,Bristol-Myers Squibb Company ,Calithera Biosciences, Inc. ,CASI Pharmaceuticals Inc. ,Cavion LLC ,Cellceutix Corporation ,Celldex Therapeutics, Inc. ,Cellectar Biosciences, Inc. ,Cellular Biomedicine Group, Inc. ,Celon Pharma Sp. z o.o. ,Celprogen, Inc. ,Celsion Corporation ,Celyad SA ,Ceronco Biosciences ,CerRx, Inc. ,Cerulean Pharma, Inc. ,Chikujee Therapeutics ,Chipscreen Biosciences Ltd ,Clovis Oncology, Inc. ,CohBar, Inc. ,Coherus BioSciences, Inc. ,Commence Bio, Inc. ,Compliment Corporation ,Corcept Therapeutics Incorporated ,Critical Outcome Technologies Inc. ,CritiTech, Inc. ,CTI BioPharma Corp. ,Cyclacel Pharmaceuticals, Inc. ,CytRx Corporation ,CZ BioMed Corp ,Debiopharm International SA ,Deciphera Pharmaceuticals, LLC ,DEKK-TEC, Inc. ,DelMar Pharmaceuticals, Inc. ,Dr. Reddy’s Laboratories Limited ,EirGenix Inc. ,Eisai Co., Ltd. ,Eli Lilly and Company ,Endocyte, Inc. ,EntreChem, S.L. ,Epigen Biosciences, Inc. ,Esperance Pharmaceuticals, Inc. ,Exelixis, Inc. ,F. Hoffmann-La Roche Ltd. ,Fate Therapeutics, Inc. ,Forty Seven Inc. ,Fujifilm Corporation ,Galena Biopharma, Inc. ,GamaMabs Pharma S.A. ,Ganymed Pharmaceuticals AG ,Gene Techno Science Co., Ltd. ,Genelux Corporation ,Genentech, Inc. ,Generex Biotechnology Corporation ,Genisphere Inc. ,Genmab A/S ,Genor BioPharma Co., Ltd. ,Gero Corp ,Gilead Sciences, Inc. ,GlaxoSmithKline Plc ,Glenmark Pharmaceuticals Ltd. ,GlycoNex Inc. ,Glycotope GmbH ,GP Pharm, S.A. ,Gradalis Inc. ,GW Pharmaceuticals Plc ,Halozyme Therapeutics, Inc. ,HEC Pharm Co., Ltd. ,Hemispherx Biopharma, Inc. ,Horizon Pharma Plc ,Ideaya Biosciences Inc ,Ignyta, Inc. ,IMMD Inc. ,Immune Design Corp. ,Immune Pharmaceuticals Inc. ,ImmunoFrontier, Inc. ,ImmunoGen, Inc. ,Immunomedics, Inc. ,Immunovaccine, Inc. ,Incyte Corporation ,Inflection Biosciences Limited ,Innate Immunotherapeutics Ltd ,Innate Pharma S.A. ,Inovio Pharmaceuticals, Inc. ,INSYS Therapeutics, Inc. ,Inventiva ,Jiangsu Kanion Pharmaceutical Co., Ltd. ,Johnson & Johnson ,Juno Therapeutics Inc. ,Karyopharm Therapeutics, Inc. ,Komipharm International Co., Ltd. ,Kyowa Hakko Kirin Co., Ltd. ,Laboratoire HRA Pharma ,Lee’s Pharmaceutical Holdings Limited ,LegoChem Biosciences, Inc ,Lymphocyte Activation Technologies, S.A. ,Mabion SA ,MabVax Therapeutics Holdings, Inc. ,MacroGenics, Inc. ,Mateon Therapeutics Inc ,MaxiVAX SA ,Mebiopharm Co., Ltd. ,Medestea Research & Production S.p.A. ,MediaPharma s.r.l. ,MedImmune, LLC ,Medivation, Inc. ,MEI Pharma, Inc. ,Merck & Co., Inc. ,Merck KGaA ,Mersana Therapeutics, Inc. ,Merus B.V. ,Midatech Pharma Plc ,Millennium Pharmaceuticals, Inc. ,Minerva Biotechnologies Corporation ,Molecular Partners AG ,MolMed S.p.A. ,Momenta Pharmaceuticals, Inc. ,Monopar Therapeutics LLC ,Morphotek, Inc. ,Mundipharma International Ltd ,Mycenax Biotech Inc. ,Natco Pharma Limited ,Nektar Therapeutics ,Nemucore Medical Innovations, Inc. ,Neovacs SA ,Nerviano Medical Sciences S.r.l. ,Neurimmune Holding AG ,Northwest Biotherapeutics, Inc. ,Novartis AG ,NovaTarg Therapeutics, Inc ,Noviga Research AB ,NuCana BioMed Limited ,Oasmia Pharmaceutical AB ,OBI Pharma, Inc. ,Omeros Corporation ,Omnitura Therapeutics Inc. ,OncBioMune Pharmaceuticals Inc. ,Oncobiologics, Inc. ,Oncodesign SA ,OncoHoldings, Inc. ,Oncolix, Inc. ,Oncolytics Biotech Inc. ,OncoMed Pharmaceuticals, Inc. ,Oncopeptides AB ,OncoTartis, Inc. ,Oncternal Therapeutics, Inc. ,Ono Pharmaceutical Co., Ltd. ,Optimum Therapeutics, LLC ,ORCA Therapeutics B.V. ,OSE Immunotherapeutics ,Otsuka Holdings Co., Ltd. ,Oxford BioMedica Plc ,Pangaea Biotech, S.L. ,Panther Biotechnology, Inc. ,PDS Biotechnology Corporation ,PEP-Therapy SAS ,Pfizer Inc. ,Pharma Mar, S.A. ,Pharmacyclics, Inc. ,PharmAust Limited ,Pharmicell Co., Ltd. ,Polaris Pharmaceuticals, Inc. ,Precision Biologics, Inc. ,Prima BioMed Ltd. ,Progen Pharmaceuticals Limited ,PsiOxus Therapeutics Limited ,Puma Biotechnology, Inc. ,Quest PharmaTech Inc. ,Recepta Biopharma S.A. ,Rexahn Pharmaceuticals, Inc. ,Rgenix, Inc. ,Richter Gedeon Nyrt. ,Rigontec GmbH ,Rosetta Genomics, Ltd. ,Sanofi ,Sanofi Pasteur SA ,Sapvax ,Satt Nord SAS ,Sellas Inc. ,Shenzen SiBiono GeneTech Co., Ltd. ,Sigma-Tau S.p.A. ,Soricimed Biopharma Inc. ,Sorrento Therapeutics, Inc. ,Sotio a.s. ,Spectrum Pharmaceuticals, Inc. ,Sphaera Pharma Pvt. Ltd. ,Starpharma Holdings Limited ,Sumitomo Dainippon Pharma Co., Ltd. ,Sun Pharma Advanced Research Company Ltd. ,Supratek Pharma Inc. ,Susavion Biosciences, Inc. ,Symic Biomedical, Inc. ,Syndax Pharmaceuticals, Inc. ,Synta Pharmaceuticals Corp. ,TaiRx, Inc. ,Takeda Pharmaceutical Company Limited ,Takis S.r.l. ,TapImmune Inc. ,Tara Immuno-Oncology Therapeutics LLC ,Targovax AS ,Tesaro, Inc. ,TetraLogic Pharmaceuticals ,Theravectys SA ,TVAX Biomedical, Inc. ,TyrNovo Ltd. ,Tyrogenex, Inc. ,ValiRx Plc ,Vascular Biogenics Ltd. ,VentiRx Pharmaceuticals, Inc. ,Verastem, Inc. ,VG Life Sciences, Inc. ,ViiV Healthcare Limited ,VioQuest Pharmaceuticals, Inc. ,ViraTherapeutics GmbH ,Vyriad ,Zensun (Shanghai) Sci & Tech Co., Ltd.

Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=647176

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
• The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects
• The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Complete research report 1780 pages with TOC is available at http://www.rnrmarketresearch.com/ovarian-cancer-pipeline-review-h1-2016-market-report.html

For more information, please visit http://www.rnrmarketresearch.com/

Contact Info:
Name: Ritesh Tiwari
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41

Source: http://marketersmedia.com/ovarian-cancer-pipeline-market-2016-global-review-covering-271-companies/125574

Release ID: 125574

Rheumatoid Arthritis Pipeline Market Global Research Covering 222 Companies

RnRMarketResearch.com adds “Rheumatoid Arthritis – Pipeline Review, H1 2016” to its database.

Pune, India – July 28, 2016 /MarketersMedia/ —

Rheumatoid Arthritis Pipeline Market Companies Involved in Therapeutics Development are 3SBio Inc. ,4D Pharma Plc ,4SC AG ,AB Science SA ,AB2 Bio Ltd. ,AbbVie Inc. ,Ablynx NV ,ACEA Biosciences, Inc. ,Addex Therapeutics Ltd ,Advinus Therapeutics Ltd ,AlphaMab Co., Ltd ,Alteogen Inc. ,Amgen Inc. ,Amura Holdings Limited ,Anacor Pharmaceuticals, Inc. ,Applied Genetic Technologies Corporation ,ARA Healthcare Pvt. Ltd. ,Arena Pharmaceuticals, Inc. ,Arrien Pharmaceuticals, LLC ,Arthrogen BV ,Asahi Kasei Pharma Corp. ,Asana BioSciences, LLC ,Astellas Pharma Inc. ,AstraZeneca Plc ,Avexxin AS ,Axxam SpA ,BCN Peptides, S.A. ,Bio-Cancer Treatment International Limited ,BIOCAD ,Biocon Limited ,Biokine Therapeutics Ltd. ,BioLingus AG ,BioLite, Inc. ,Bionovis SA ,BioTherapeutics Inc. ,Bird Rock Bio, Inc. ,Boehringer Ingelheim GmbH ,Bone Medical Limited ,Boryung Pharmaceutical Co., Ltd. ,Bristol-Myers Squibb Company ,Can-Fite BioPharma Ltd. ,Cardax Pharmaceuticals, Inc. ,CASI Pharmaceuticals Inc. ,CEL-SCI Corporation ,Celgene Corporation ,Cellceutix Corporation ,Celltrion, Inc. ,ChemoCentryx, Inc. ,Chipscreen Biosciences Ltd ,ChironWells GmbH ,Chong Kun Dang Pharmaceutical Corp. ,CJ HealthCare Corp. ,CLL Pharma ,Clonz Biotech Private Limited ,Coherus BioSciences, Inc. ,Commence Bio, Inc. ,Compugen Ltd. ,Confluence Life Sciences, Inc. ,CSL Limited ,Cyclacel Pharmaceuticals, Inc. ,Daiichi Sankyo Company, Limited ,Diamyd Medical AB ,Domainex Limited ,Dr. Reddy’s Laboratories Limited ,Eisai Co., Ltd. ,Eli Lilly and Company ,Enceladus Pharmaceuticals BV ,Endocyte, Inc. ,Enzene Biosciences Ltd. ,Epirus Biopharmaceuticals, Inc. ,F. Hoffmann-La Roche Ltd. ,Five Prime Therapeutics, Inc. ,Fountain Biopharma Inc. ,Galapagos NV ,Gene Techno Science Co., Ltd. ,Genentech, Inc. ,Genor BioPharma Co., Ltd. ,Genosco ,Gilead Sciences, Inc. ,GlaxoSmithKline Plc ,Griffin Discoveries BV ,Han Wha Pharma Co., Ltd. ,Handok Inc. ,Hanmi Pharmaceuticals, Co. Ltd. ,Hansa Medical AB ,Hanwha Chemical Corporation ,HEC Pharm Co., Ltd. ,Hetero Drugs Limited ,HitGen LTD ,Huabo Biopharm Co., Ltd. ,Hutchison MediPharma Limited ,Idera Pharmaceuticals, Inc. ,Idogen AB ,Immune Response BioPharma, Inc. ,Immungenetics AG ,ImmunoFrontier, Inc. ,Innate Pharma S.A. ,Innovent Biologics, Inc. ,Intas Pharmaceuticals Ltd. ,ISU ABXIS Co.,Ltd. ,JHL Biotech, Inc. ,Jiangsu Hengrui Medicine Co., Ltd. ,Johnson & Johnson ,Jyant Technologies, Inc. ,Kadmon Corporation, LLC ,KAHR medical Ltd. ,Kang Stem Biotech Co., Ltd. ,Karus Therapeutics Limited ,Karyopharm Therapeutics, Inc. ,Kezar Life Sciences, Inc. ,Kineta, Inc. ,Kolltan Pharmaceuticals, Inc. ,Lead Pharma Holding B.V. ,Lexicon Pharmaceuticals, Inc. ,LG Life Science LTD. ,Lipocure Ltd. ,LSK BioPartners, Inc. ,Lupin Limited ,Mabion SA ,Mabtech Limited ,mAbxience S.A. ,MacroGenics, Inc. ,Mebiopharm Co., Ltd. ,MedAnnex Ltd ,Medestea Research & Production S.p.A. ,MediGene AG ,MedImmune, LLC ,Mesoblast Limited ,Millennium Pharmaceuticals, Inc. ,Mitsubishi Tanabe Pharma Corporation ,Modern Biosciences Plc ,ModiQuest Group ,Momenta Pharmaceuticals, Inc. ,Morphotek, Inc. ,Mycenax Biotech Inc. ,MYOS RENS Technology Inc. ,Myungmoon pharmaceutical Co., Ltd. ,NanoSmart Pharmaceuticals, Inc. ,Navigen Pharmaceuticals, Inc. ,Neovacs SA ,Nimbus Therapeutics, LLC ,Nissan Chemical Industries, Ltd. ,Novartis AG ,NovImmune SA ,Nuevolution AB ,Omeros Corporation ,Oncobiologics, Inc. ,Oncodesign SA ,OncoImmune, Inc. ,Ono Pharmaceutical Co., Ltd. ,OPKO Health, Inc. ,Opsona Therapeutics Limited ,Oscotec Inc. ,OSE Immunotherapeutics ,Panacea Biotec Limited ,Paras Biopharmaceuticals Finland Oy ,Parvus Therapeutics, Inc. ,Peptinov SAS ,Pfenex Inc. ,Pfizer Inc. ,Pharmacyclics, Inc. ,Pharmedartis GmbH ,Phenex Pharmaceuticals AG ,Philogen S.p.A. ,PLx Pharma Inc. ,Principia Biopharma Inc. ,Progenra, Inc. ,ProNoxis AB ,ProtAb Ltd ,Protagonist Therapeutics Inc. ,Protalex, Inc. ,Protalix BioTherapeutics, Inc. ,Qu Biologics Inc. ,R-Pharm ,Re-Pharm Limited ,ReceptoPharm, Inc. ,RedHill Biopharma Ltd. ,Redx Pharma Plc ,Regeneron Pharmaceuticals, Inc. ,Resverlogix Corp. ,ReveraGen BioPharma, Inc. ,Rhizen Pharmaceuticals S.A. ,Richter Gedeon Nyrt. ,Saje Pharma, LLC ,Sandoz International GmbH ,Sareum Holdings Plc ,SBI Biotech Co., Ltd. ,Selvita S.A. ,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ,Shanghai Henlius Biotech Co., Ltd. ,Shanghai Pharmaceutical Co., Ltd. ,Swedish Orphan Biovitrum AB ,Synovo GmbH ,Syntrix Biosystems, Inc. ,TaiwanJ Pharmaceuticals Co., Ltd. ,Takeda Pharmaceutical Company Limited ,TechnoPhage SA ,Teijin Pharma Limited ,The International Biotechnology Center (IBC) Generium ,TheraMAB LLC ,Therapeutic Proteins International, LLC ,TiGenix NV ,Toleranzia AB ,Tumorend, LLC ,TxCell SA ,U.S. Stem Cell, Inc. ,UCB S.A. ,United BioPharma, Inc. ,Vaccinex, Inc. ,Valeant Pharmaceuticals International, Inc. ,Vichem Chemie Research Ltd. ,Vicore Pharma AB ,Vida Therapeutics Inc. ,Vitae Pharmaceuticals, Inc. ,Vitaeris Inc ,Xbrane Biopharma AB ,Xencor, Inc. ,XTL Biopharmaceuticals Ltd. ,Yungjin Pharm. Co., Ltd. ,Yuyu Pharma, Inc. ,Zenyaku Kogyo Co., Ltd. ,Zydus Cadila Healthcare Limited.

Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=647177

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
• The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
• The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For more information, please visit http://www.rnrmarketresearch.com/

Contact Info:
Name: Ritesh Tiwari
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41

Source: http://marketersmedia.com/rheumatoid-arthritis-pipeline-market-global-research-covering-222-companies/125572

Release ID: 125572

IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stericycle, Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 28, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against Stericycle, Inc. (“Stericycle” or the “Company”) (Nasdaq: SRCL, SRCLP). Investors who purchased or otherwise acquired shares between February 7, 2013 and April 28, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 12, 2016 lead plaintiff motion deadline.

If you purchased shares of Stericycle during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Stericycle failed to disclose that it engaged in a scheme whereby it routinely raised the rates it charged smaller customers in violation its contracts with those customers. This inflated revenues and growth. On October 22, 2015, the Company announced disappointing growth rates and revenues during the third quarter of 2015. On April 28, 2016, Stericycle disclosed its results for the first quarter of 2016 which were again below expectations. When this information was disclosed, the Company’s stock price decreased significantly.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442983

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Halyard Health, Inc. & Kimberly-Clark Corporation and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 28, 2016 / Lundin Law PC (the “Firm”) announces that a class action lawsuit was filed against Halyard Health, Inc. (“Halyard” or the “Company”) (NYSE: HYH) on behalf of investors who purchased or otherwise acquired shares (1) on or after February 25, 2013 and subsequently received Halyard securities pursuant to the spin-off of Kimberly-Clark Corporation (NYSE: KMB) from Halyard, effective as of October 31, 2014; and/or (2) purchased or otherwise acquired Halyard securities between October 21, 2014 and April 29, 2016, both dates inclusive (collectively, the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws.

Investors who purchased or otherwise acquired shares during one of those periods should contact the Firm in advance of the August 29, 2016 lead plaintiff
motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that the Company issued misleading statements and/or failed to disclose that: the Company’s MICROCOOL surgical gowns consistently failed effectiveness tests and failed to meet industry standards; and Kimberly-Clark and Halyard had knowingly provided defective MICROCOOL surgical gowns to U.S. workers during the Ebola crisis. When this information was disclosed, shares of Halyard stock dropped in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to securing shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442980

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neovasc Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 28, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN). Investors who purchased or otherwise acquired shares between January 26, 2015 and May 19, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August
5, 2016 lead plaintiff motion deadline.

If you purchased shares of Neovasc during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Neovasc made false and misleading statements and/or failed to disclose: that the Company’s Tiara device was developed through unlawful business practices such as misappropriation of trade secrets; that a related lawsuit against Neovasc regarding the misappropriation of trade secrets had merit; and that as a result of the above, the Company’s statements about business, operations, and prospects were materially false and misleading at all relevant times.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442979

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against K12, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 28, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against K12, Inc. (“K12” or the “Company”) (NYSE: LRN) concerning possible violations of federal securities laws between November 7, 2013 and October 27, 2015 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 19, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, K12 issued false and misleading statements and/or failed to disclose: that the Company published misleading advertisements about students’ academic progress, parent satisfaction, graduates’ eligibility for admission into the University of California and California State University, class sizes, the individualized and flexible nature of K12’s instruction, hidden costs, and the quality of the materials provided to students; that the Company submitted inflated student attendance numbers to the California Department of Education in order to receive additional funding; that K12 was open to potential civil and criminal liability due to these practices; that K12 would likely be forced to end these practices, which would have a negative impact on its operations and prospects; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was disclosed, investors suffered damages.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442978

5-DAY DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Banco Bradesco S.A. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 28, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Banco Bradesco S.A. (“Banco Bradesco” or the “Company”) (NYSE: BBD, BBDO). Investors who purchased or otherwise acquired shares between April 30, 2012 through May 31, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August 2, 2016 lead plaintiff motion deadline.

If you purchased shares of Banco Bradesco during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made materially false and/or misleading statements and failed to disclose that: Banco Bradesco was involved in bribery with the Brazilian Finance Ministry’s CARF; the Company’s executives were planning on avoiding a $828 million tax fine by Brazil’s Internal Revenue Service; several of Banco Bradesco’s CEO, executives, directors, and employees were engaged in bribery, corruption, and money laundering; Banco Bradesco’s internal control of financial reporting, procedures, and disclosure controls were ineffective; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On May 31, 2016 news reports disclosed that the Company’s CEO was indicted by Brazilian police on corruption charges. When this news was announced on May 31, 2016, shares of Banco Bradesco fell nearly 6% on that same day.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442977

Falcon Gold Private Placement

VANCOUVER, BC / ACCESSWIRE / July 28, 2016 / FALCON GOLD CORP. (TSXV: FG) (“Falcon” or the “Company”) announces that further to its July 22 news release whereby the Company announced a non-brokered private placement of up to 7.27 million Units priced at $0.055 per Unit for proceeds of up to $400,000, the Company contemplates that various exemptions will be utilized pursuant to this funding and it may rely upon the suitability advice exemption (B.C. Instrument 45-536) for a portion thereof. There is no material fact or material change that has not been generally disclosed.

Each Unit will consist of one (post-consolidated) common share and one (post-consolidated) 2 year common share purchase warrant. Each warrant will be exercisable for one common share at $0.10 for 2 years following the closing. The shares will be subject to a 4 month hold period and the private placement is subject to TSX Venture Exchange approval.

Proceeds from this financing shall be used for investigating project acquisitions, and general corporate purposes.

About Falcon Gold Corp.

Falcon is a Canadian mineral exploration company focused on generating, acquiring, and exploring opportunities in the Americas.

On Behalf of the Board,

“David G. Tafel”
Chairman

For additional information, please visit our website: www.falcongold.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward looking statements concerning future operations of Falcon Gold Corp. (the “Company”). All forward looking statements concerning the Company’s future plans and operations, including management’s assessment of the Company’s project expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company’s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and exploration and financial results may differ materially from any estimates or projections.

SOURCE: Falcon Gold Corp.

ReleaseID: 442974

Gourmet Living Tuscany Luxury Extra Virgin OIive Oil New Product Launched

Gourmet Living has launched a new extra virgin olive oil from Tuscany, with a a high quality blend of Italian oils. The focus of the company is bringing the best quality gourmet foods to the average consumer’s attention.

Greenwich, United States – July 28, 2016 /PressCable/ —

A new Tuscan extra virgin olive oil blend has been launched. Harvested on the rolling hills of south Florence, it is harvested and pressed from the three main olive varieties of Firenze: Frantoio, Moraiolo, and Leccino. This olive oil are especially selected for their superior quality and aroma, and the company selling them, Gourmet Living, has announced a summer promotional discount.

More information can be found on the Gourmet Living extra virgin olive oil Amazon page listing at: http://amazon.com/Extra-Virgin-Olive-Oil-Italy/dp/B0176MOT74.

The listing page on Amazon explains that customers buying the authentic, luxurious and high quality olive oil will receive a product that has been estate bottled in Italy and verified by Italian authorities. Extra virgin olive oil is at the heart of the Mediterranean diet, and is one of the reasons why their diet is considered to be one of the healthiest in the world.

Gourmet Living extra virgin olive oil has a wide range of uses, and many of them are listed on the Amazon page, including application as a skin moisturizer and hair conditioner. The site underscores that it is best used in food, however, says that it’s here where the high quality ingredients excel.

The gourmet olive oil is fully organic, with low free acidity of less than 0.8% as required by the International Olive Oil Council guidelines. Customers can impress their diners with a huge selection of olive oil inspired recipes, including fresh salads and vegetables using Gourmet Living’s extra virgin olive oil.

The Gourmet Living site explains that the company’s primary goal is to enrich the lives of its customers through a disciplined and educational approach to discovering and using great food products from around the world.

Started by husband and wife team Richard and Sheila May, they bring nutritionist and advertising experience to the fore, and over the last 20 years have experienced the rich and diverse array of foods available around the world.

The company said: “Many so-called healthy or organic foods are hardly healthy or truly organic. As such, my husband and I decided to seek out great natural products that we believe are essential to any home cook.”

For more information, please visit http://gourmetliving.org/

Contact Info:
Name: Sheila May
Organization: Gourmet Living
Address: 20 Church Street, B-61, Greenwich, CT 06830
Phone: +1 866 554 5277

Release ID: 125076